Bright Minds Biosciences Inc., a biotechnology company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
History
Bright Minds Biosciences was founded in 2019 by a group of scientists and engineers passionate about advancing the realm of neuroscience through innovative treatments.
Mission
Our mission is to develop treatments for neurological disorders that improve the quality of life of affected individuals.
Vision
Our vision is to create a world where neurological health is improved, so everyone can live their best lives. We are dedicated to creating products that not just improve lives, but save lives, too.
